First evaluation using a validated scale of the risk of congestive heart failure among hypertensive patients treated by general practitioners (O-PREDICT survey)  by Hagège, Albert Alain et al.
Archives of Cardiovascular Disease (2010) 103, 176—183
CLINICAL RESEARCH
First evaluation using a validated scale of the risk of
congestive heart failure among hypertensive patients
treated by general practitioners (O-PREDICT survey)
Première évaluation à partir d’une échelle validée du risque d’insufﬁsance
cardiaque chez des patients hypertendus vus en médecine générale (enquête
O-PREDICT)
Albert Alain Hagègea,∗, Nacima Demilb,
Gilles Errieauc, Jean-Franc¸ois Aupetitd,
Franc¸ois Dievarte, Jean-Jacques Mouradf
a Inserm U 633, pôle cardiovasculaire, hôpital européen Georges-Pompidou, Assistance
publique—Hôpitaux de Paris, université Paris Descartes, 20, rue Leblanc, 75015 Paris, France
b Laboratoire AstraZeneca, 92844 Rueil-Malmaison, France
c Cabinet médical, 75014 Paris, France
d Centre hospitalier Saint-Joseph et Saint-Luc, 69007 Lyon, France
e Nouvelle clinique Villette, 59240 Dunkerque, France
f Hôpital Avicenne, 93000 Bobigny, France
Received 25 June 2009; received in revised form 17 January 2010; accepted 19 January 2010
Available online 11 March 2010
KEYWORDS
Hypertension;
Heart failure;
Risk factors
Summary
Background.— Routine management of hypertensive adults is based on assessment of risk fac-
tors for coronary artery disease; risk factors for heart failure (HF) remain poorly investigated
despite the key role of hypertension in HF development.
Aim.— To assess the components of HF risk in hypertensive adults in primary care, compare
physicians’ estimations of HF and global cardiovascular risks with established calculation algo-
rithms, and assess the concordance of these algorithms.
Methods.— O-PREDICT was a transverse, observational, multicentre French survey conducted
in 2006 among general practitioners who included the ﬁrst hypertensive, non-HF patient seen in
each of three age classes (< 60, 60—70, > 70 years). Estimations of HF and global cardiovascular
Abbreviations: BMI, Body mass index; BP, Blood pressure; GP, General practitioner; HF, Heart failure; SCORE, Systemic Coronary
Risk Evaluation.
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risks (at 4 and 10 years, respectively) were performed subjectively during the consultation and
calculated a posteriori according to algorithms from the Framingham cohort and the European
SCORE database, respectively. For each of these methods, patients were stratiﬁed into four risk
categories (i.e., no, low, moderate, high).
Results.— One thousand ﬁve hundred and thirty seven physicians recruited 4523 patients (61%
men; 64.5± 10.9 years; systolic blood pressure 149.9± 15.4mmHg); most (67.2%) patients had
one or two cardiovascular/HF risk factors (dyslipidaemia 48.8%, left ventricular hypertrophy
25.3%, diabetes 18.8%, coronary artery disease 8.8%, valvulopathy 6.1%); the number increased
with advancing age and in men versus women. According to the Framingham algorithm, the risk
of HF (mean 5.4± 8.5%; 13.4% of patients at high risk) increased with advancing age (p < 0.001),
nearly doubling for each decade increase. According to the European SCORE system, global car-
diovascular risk (mean 5.4± 4.3%) was moderate or elevated in 48.1% of patients. Concordance
between physicians’ estimations and theoretical calculations for HF and global risks was poor,
as was concordance between algorithms (w = 0.28, 0.12, 0.11, respectively).
Conclusion.— More than one in 10 hypertensive patients seen in primary care is at high risk of
HF at 4 years according to the Framingham model; this algorithm appears to offer additional
information to that provided by the SCORE system. Physicians’ estimations of risks correlated
poorly with algorithm calculations, suggesting that the use of these tools in general practice
should be encouraged.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Justiﬁcation.— La prise en charge des adultes hypertendus est généralement basée sur
l’évaluation des facteurs de risque de coronaropathie, alors que les facteurs de risque
d’insufﬁsance cardiaque (IC) restent peu évalués malgré le rôle crucial de l’hypertension
artérielle dans le développement de l’IC.
Objectifs.— Évaluer les composantes du risque d’IC chez des patients hypertendus vus en
médecine générale, et comparer les estimations par le médecin du risque d’IC et du risque
cardiovasculaire global par rapport au risque calculé par des échelles validées, et enﬁn évaluer
la concordance entre ces deux estimations.
Méthode.— O-PREDICT est une étude observationnelle, transversale, multicentrique conduite
en France en 2006 chez des médecins généralistes qui devaient inclure le premier patient hyper-
tendu sans IC vu en consultation au sein de trois tranches d’âge (< 60, 60—70, > 70 ans). Les
estimations du risque d’IC et du risque cardiovasculaire global (à 4—10 ans, respectivement)
étaient réalisées de fac¸on subjective pendant la consultation et calculées a posteriori sur des
algorithmes publiés basés sur la cohorte de Framingham et le SCORE Européen, respectivement.
Pour chacune de ces trois méthodes, les patients étaient classés en quatre catégories de risque:
(nul, faible, modéré ou élevé).
Résultats.— Mille cinq cent trente-sept médecins ont recruté 4523 patients (61 % d’hommes ;
âge 64,5± 10,9 ans ; pression artérielle systolique: 149,9± 15,4mmHg), la majorité (67,2 %)
avec un ou deux facteurs de risque cardiovasculaire/IC [dyslipidémie (48,8 %), hypertrophie
ventriculaire gauche (25,3 %), diabète (18,8 %), coronaropathie (8,8 %), valvulopathie (6,1 %)],
facteurs plus fréquents avec l’âge et chez les hommes. Selon l’algorithme de Framingham, le
risque d’IC (moyenne 5,4± 8,5 % ; risque élevé chez 13,4 % des patients) doublant presque pour
chaque décade d’âge (p < 0,001). Selon l’algorithme SCORE, le risque cardiovasculaire global
(moyenne 5,4± 4,3 %), était modéré ou élevé pour 48,2 % des patients. Les concordances entre
les estimations du médecin et les calculs des risques d’IC et cardiovasculaire global étaient
mauvaises, de même que la concordance entre les deux algorithmes (w = 0,28, 0,12 et 0,11,
respectivement).
Conclusion.— Plus d’un patient hypertendu sur dix vus en médecine générale est à haut risque
de développer une IC à quatre ans selon l’algorithme de Framingham, qui semble complé-
mentaire de l’échelle SCORE. La corrélation entre les risques estimés par le médecin et les
risques calculés restent faibles, ce qui devrait encourager à utiliser ces algorithmes en médecine
générale.
© 2010 Elsevier Masson SAS. Tous droits réservés.
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ackground
he routine management of hypertensive adults is based
n the assessment of risk factors for coronary artery dis-
ase [1,2] and on the concept of global cardiovascular
isk. Concomitant intensive management of multiple risk
actors has emerged as a useful approach for risk reduc-
ion [3—8]. Thus, the European Systematic Coronary Risk
valuation (SCORE) system has been proposed to provide
numerical score related to different risk factors such
s sex, age, smoking status, systolic blood pressure (BP),
otal cholesterol and diabetes, in order to stratify individual
atients according to their 10-year risk for coronary artery
isease mortality [9]. Recalibration of this algorithm is nec-
ssary in low-risk European populations, such as in France
10—12].
Recent American and European recommendations con-
erning the management of chronic heart failure (HF) have
ighlighted high BP as one of the main precipitating fac-
ors [13,14]. These guidelines have also identiﬁed a group
f at-risk patients without clinically evident disease or struc-
ural cardiac abnormalities, but with classic risk factors
or HF, who should form an important focus for modern
ealthcare policies. It remains that HF risk factors, partic-
larly in hypertensive patients, are poorly investigated in
urrent clinical practice despite the key role of hyperten-
ion in HF development. An analysis from the Framingham
ohort has shown that identiﬁcation of patients at high risk
f developing HF within 4 years is possible using a calcula-
ion algorithm, which takes into account risk factors for HF
ncluding arterial pressure [15]. However, these validated
ools are not currently used in clinical practice, and both
F and cardiovascular risks appear to be underestimated,
articularly in patients at highest risk [16].
Thus, the aims of the Observatoire de la prise en charge
t de l’évaluation du risque d’insufﬁsance cardiaque chez
es patients hypertendus (O-PREDICT) survey, conducted by
rench general practitioners (GPs) during routine practice,
ere to assess the components of HF risk in hypertensive
dults in primary care and to compare physicians’ estima-
ions of HF and global cardiovascular risks with those from
stablished algorithms.
ethods
he O-PREDICT survey was a transverse, observational, mul-
icentre survey conducted by GPs in France from March 2006
o July 2006. Each GP included the ﬁrst adult (age≥ 18 years)
ypertensive, non-HF patient seen in each of three age
lasses (< 60, 60—70, > 70 years). Hypertension was deﬁned
s systolic BP≥ 140mmHg and/or diastolic BP≥ 90mmHg or
reated hypertension.
The primary study objective was to assess the incidence
f each component of HF risk in hypertensive patients free
f HF in primary care. Secondary objectives were to cal-
ulate the 4-year risk of HF according to the Framingham
ohort [15] and the 10-year global cardiovascular risk using
he European SCORE system [17], and then to compare
he physicians’ estimations done during the GP visit with
hese calculations performed a posteriori. The concordance
etween both risk calculations was analysed.
b
e
e
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ata collection and risk estimations
questionnaire was completed by the physician for each
atient, which collected clinical information, medical and
ardiovascular history, cardiovascular risk factors deﬁned by
he French Haute Autorité de santé [18], clinical symptoms,
utpatient and ambulatory BP measurements when avail-
ble, complementary investigations, and BP history. Based
n these data, GPs estimated the 4-year HF risk and the 10-
ear global cardiovascular risk level for each patient as no
isk, low, moderate or high risk.
isk calculations
oth risks were then calculated a posteriori from the ﬁnal
atabase, using algorithms for men and women, and for each
ge category, to be crossed with the physicians’ estimations.
he 4-year HF risk was calculated based on the predis-
osing conditions from the Framingham cohort [15] (i.e.,
ge, systolic BP, heart rate, electrocardiographic and/or
chocardiographic left ventricular hypertrophy, body mass
ndex [BMI], coronary artery disease, valvulopathy and dia-
etes). The 10-year global cardiovascular risk was calculated
ccording to the European SCORE system, based on sex, age,
moking status, systolic BP and cholesterol concentration
17]. Patients were stratiﬁed consecutively into four levels
f risk: no risk (≤ 1%), low (2—4%), moderate (5—9%) and
igh (≥ 10%) risk for HF at 4 years, and no risk (≤ 1%), low
2—4%), moderate (5—14%) and high (≥ 15%) risk for global
ardiovascular risk at 10 years.
oncordance between HF and cardiovascular
isk calculations
o analyse concordance between the Framingham HF risk
odel and the SCORE system, the following risk categories
ere used: ≤ 1%, 2—4%, 5—9%, 10—14% and ≥ 15%.
tatistical analysis
he assessment was done for the whole population as well
or each sex andwithin age categories. Based on an expected
inimal percentage of 4% of patients presenting with a car-
iovascular factor included in the HF risk assessment and
survey accuracy ﬁxed to 1.5%, the number of patients
eeded in each group was estimated to be 656 (i.e., 1640
atients in each age group for an expected maximal sex
atio of 1.5), with a total of 4920 patients for the survey
19]. Descriptive statistics were mean, standard deviation,
inimum, maximum and median values for quantitative
arameters, and frequency and percentage for qualitative
arameters. Between-group comparisons were made using
he t-test for continuous variables and the Chi-square test
or categorical variables. Multivariable regression analyses
ere used to assess the independent prognostic value of
ariables in Cox models and results are expressed as odds
atios with 95% conﬁdence intervals; hence, concordance
etween the GPs’ estimates of risk and the calculated lev-
ls according to the Framingham or the SCORE system was
valuated using weighted kappa (w). To interpret the kappa
atings, benchmarks were used as suggested by Landis and
och [20]. All tests were bilateral with a ˛ risk equal to
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Table 1 Patient characteristics.
Total Men Women pa
Patients, n (%) 4523 2765 (61.1) 1758 (38.9)
Age in yearsb, n (%) 64.5± 10.9 — —
<60 1527 (33.8) 1059 (38.3) 468 (26.6) ND
60—70 1531 (33.9) 900 (32.5) 631 (35.9) ND
> 70 1465 (32.4) 806 (29.2) 659 (37.5) ND
Systolic BPb (mmHg) 149.9± 15.4 150.3± 15.0 149.4± 15.8 0.032
Diastolic BP (mmHg) 86.8± 10.2 87.3± 10.1 85.9± 10.2 ND
Heart rateb (beats/minute) 74.9± 9.0 74.8± 9.1 75.0± 8.7 0.39
BMIb (kg/m2) 27.7± 4.6 27.9± 4.1 27.5± 5.3 0.006
BMI > 30 kg/m2, n (%) 1104 (24.8) 662 (24.4) 442 (25.6) ND
Total cholesterol (g/L) 2.2± 0.4 2.2± 0.4 2.2± 0.4 ND
High-density lipoprotein cholesterol (g/L) 0.6± 0.2 0.6± 0.2 0.6± 0.2 ND
Dyslipidaemia, n (%) 2063 (48.8) 1312 (50.8) 751 (45.8) ND
Sedentary lifestyle, n (%) 2909 (64.0) 1695 (60.1) 1214 (68.7) ND
Alcohol misuse, n (%) 956 (21.3) 852 (31.1) 104 (6.0) ND
Diabetesb, n (%) 842 (18.8) 542 (19.7) 300 (17.2) 0.0026
Left ventricular hypertrophyb,c, n (%) 816 (25.3) 535 (26.6) 281 (23.3) 0.0004
Coronary artery diseaseb, n (%) 392 (8.8) 301 (11.1) 91 (5.25) < 0.0001
Heart valve diseaseb, n (%) 270 (6.1) 162 (6.0) 108 (6.3) 0.41
Symptoms/abnormal signs, n (%) 1710 (38.2) 997 (36.4) 713 (41.0) ND
Exertion dyspnoea 1118 (65.4) 635 (63.7) 483 (67.7) ND
Lower limb oedema 447 (26.1) 234 (23.5) 213 (29.9) ND
Cardiac murmur 271 (15.9) 171 (17.2) 100 (14.0) ND
Palpitations 223 (13.0) 148 (14.8) 75 (10.5) ND
Sleep apnoea syndrome 214 (12.5) 181 (18.2) 33 (4.6) ND
Data expressed as mean± standard deviation except where indicated. BMI: body mass index; BP: blood pressure; LVH: left ventricular
hypertrophy; ND: not done.
a For men vs women.
b Components of heart failure risk.
c On electrocardiogram and/or echocardiograph.
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60.05. Statistical analysis was performed using SAS® software,
version 8.2 (SAS Instituted Inc, Cary, NC, USA).
Results
Study-group characteristics
A total of 1537 GPs from all metropolitan areas in France
participated in the O-PREDICT survey. Of the 4585 recruited
patients, 62 (1.4%) were excluded from the analysis due
to major deviations such as missing age (n = 42) and sex
(n = 19), or normal BP and no antihypertensive treatment
(n = 2). Consequently, 4523 hypertensive adult patients
with a mean age of 65± 11 years formed the study
group. The characteristics of these patients are shown in
Table 1. Sex distribution was similar across the three age
groups.
The time since diagnosis of hypertension was described as
recent (new diagnosis or within past year) (20.3%, n = 917),
between 1 and 10 years (59%, n = 2658) and > 10 years (20.7%,
n = 932). Women (23.5% vs 18.9% in men) and patients
older than 70 years (39.3%) were more likely to have
been diagnosed with hypertension more than 10 years ear-
lier.
B
l
t
tLifestyle considerations revealed current smoking in
9.4%, alcohol misuse in 21.3% and sedentary behaviour in
4.0% of patients. Obesity (BMI > 30 kg/m2) was reported in
6.6% of patients aged < 60 years and in 28.2% between 60
nd 70 years of age, but in only 19.8% of patients > 70 years.
Compared to women, men presented with higher sys-
olic BP and BMI, and more often with left ventricular
ypertrophy, coronary artery disease or diabetes. Compared
o younger patients, older patients (> 70 years) pre-
ented with higher systolic BP (p = 0.057), BMI (p < 0.0001)
nd more frequently with left ventricular hypertrophy,
oronary artery disease, cardiac valve disease or dia-
etes (p < 0.0001 for each). In men > 50 years of age
93.6%; n = 2498) and women > 60 years (75.8%; n = 1287),
ost patients (67.2%; n = 3037) presented one or two
isk factors and 19.5% (n = 883) with three risk factors,
ncluding family history of coronary artery disease (25.7%;
= 1150), current smoking (19.4%; n = 867), diabetes (18.8%;
= 842) and dyslipidaemia (48.8%; n = 2063), while only
.0% (n = 272) presented no cardiovascular risk factors.
eyond 70 years of age, the prevalence of diabetes, dys-
ipidaemia and family history of coronary artery disease
ended to decrease while the rate of systolic hyper-
ension increased. The number of risk factors increased
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Table 2 Calculated heart failure risk at 4 years accord-
ing to the Framingham algorithm [15] in men and women
and within each age class.
Age (years) Men (n = 1856) Women (n = 983)
< 60 2.4 ± 2.9 2.0 ± 1.9
60—70 4.4 ± 5.6 5.0 ± 8.6
> 70 8.6 ± 10.2 8.9 ± 12.6
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igniﬁcantly in patients with left ventricular hypertrophy
p < 0.001).
Coronary artery disease was reported in 8.8% of patients
previous myocardial infarction in 202 patients and/or
oronary revascularization in 201 patients). Peripheral arte-
iopathy was reported in 8.9% (n = 394), heart valve disease
n 6.1% (n = 270), renal dysfunction in 4.7% (n = 209) and pre-
ious stroke in 3.4% (n = 163). Cardiovascular drugs (mean
.3± 1.4) were taken by 88.5% patients (n = 3994).
eart failure risk
hysician estimation
he risk of developing HF over 4 years was estimated by the
Ps to be none in 6.3% (n = 281), low in 36.8% (n = 1651),
oderate in 37.3% (n = 1673) and high in 19.7% (n = 882) of
atients. The incidence of moderate or high risk increased
ith advancing age (Table 2 and Fig. 1), and was higher in
en compared with women (61.2% vs 50.2%, respectively).
heoretical calculation
he risk of developing HF over 4 years was evaluated in
839 (62.8%) patients and reached a mean of 5.4± 8.5%
corresponding score 10.9± 5.3 points). The risk increased
igniﬁcantly with age (p < 0.001), nearly doubling for each
ecade increase (Table 2). When considering categorical risk
evels, 11.5% of patients (n = 325) were considered as hav-
ng no risk, 61.1% (n = 1734) as at low risk, 14.1% (n = 399)
t moderate risk and 13.4% (n = 381) at high risk. The
ates of moderate and high risk increased with age, reach-
ng 3.2% < 60 years, 10.3% between 60 and 70 years, and
4.3% > 70 years of age. The estimated incidence of mod-
rate or high risk rose with advancing age and was higher in
en versus women (Fig. 1).
omparison of calculated and estimated risks
oncordance between the estimated and calculated risks
as poor (40.6%; w = 0.28) (Table 3), irrespective of the
resence or absence of symptoms (41.1% for the 1197 symp-
omatic patients versus 40.1% for the 1616 asymptomatic
ubjects). Physicians tended to overestimate the risk of
eveloping HF, irrespective of the patient’s sex and age; the
isk of overestimation was by one step in 37.8% (n = 1067)
nd by two steps in 11.2% (n = 316) of patients. Concordant
stimations were more frequent in women (46.2%; n = 453)
han in men (37.6%; n = 694), and increased with age (32.1%
n = 261] < 60 years, 42.0% [n = 477] between 60 and 70 years
nd 46.0% (n = 477) > 70 years).
O
g
T
i
cigure 1. Percentage of patients in each category of heart failure
isk according to sex and age group, according to the Framingham
lgorithm.
lobal cardiovascular risk
hysician estimation
he global cardiovascular risk was estimated to be none in
.3% (n = 58), low in 23.4% (n = 1044), moderate in 41.2%
n = 1841) and high in 34.2% (n = 1529) of patients. The preva-
ence of high-risk patients increased with age (26.9—41.7%)
nd was higher in men than in women (38.6% vs 27.2%).
heoretical calculation
f the 4523 participants, it was possible to calculate the
lobal cardiovascular SCORE risk in 3341 (73.9%) patients.
he mean score was 5.4± 4.3. When considering categor-
cal risk levels (Table 4), 11.1% (n = 367) of patients were
onsidered as at no risk, 40.8% (n = 1351) as at low risk, 43.8%
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Table 3 Concordance between risk of heart failure at 4 years estimated by general practitioners or calculated according
to the Framingham algorithm [15]. The number of patients concerned (percentage of overall population) is given for each
category of heart failure risk (w = 0.28).
Estimated No risk Low risk Moderate risk High risk Total
Calculated
No risk 62 (2.2) 69 (2.4) 2 (0.1) 0 (0) 133 (4.7)
Low risk 173 (6.1) 668 (23.7) 77 (2.7) 16 (0.6) 934 (33.1)
Moderate risk 66 (2.3) 742 (26.3) 166 (5.9) 111 (3.9) 1085(38.4)
High risk 20 (0.7) 250 (8.9) 152 (5.4) 251 (8.9) 673 (23.8)
Total 321 (11.3) 1729 (61.2) 397 (14.1) 378 (13.4) 2825 (100)
Table 4 Concordance between cardiovascular risk at 10 years estimated by the general practitioners and calculated
according to the global cardiovascular SCORE system [17]. The number of patients concerned (percentage of overall
population) is given for each category of heart failure risk (w = 0.11).
Estimated No risk Low risk Moderate risk High risk Total
Calculated
No risk 20 (0.6) 153 (4.7) 133 (4.0) 61 (1.8) 367 (11.1)
Low risk 19 (0.6) 335 (10.1) 587 (17.7) 410 (12.4) 1351(40.8)
Moderate risk 3 (0.1) 229 (6.9) 582 (17.6) 635 (19.2) 1449(43.8)
53 (1.6) 84 (2.5) 144 (4.3)
1355 (40.9) 1190 (35.9) 3311 (100)
F
o
a
i
D
OHigh risk 0 (0) 7 (0.2)
Total 42 (1.3) 724 (21.9)
(n = 1449) at moderate risk, and 4.3% (n = 144) at high-risk.
Men presented with a higher mean score compared to
women (7.0± 4.7 vs 3.1± 2.0) and were more often at mod-
erate (60.6% vs 18.3%) or high (7.3% vs 0%) risk. In addition,
patients aged 60—70 years presented with the highest mean
score (6.81± 4.8) and the highest frequency of moderate to
high risk (60.4% vs 58.3% in patients > 70 years and 27.6% in
patients < 60 years).
Comparison of calculated and estimated risks
Concordance between the estimated and calculated risks
was mild (30.8%; w = 0.11; Table 4). GPs tended to under-
estimate the no risk and low risk categories and to
overestimate the high risk in both men and in women. Over-
all, 41.5% (n = 1375) of patients had their risk overestimated
by one step, 16.4% (n = 543) by two steps and 1.8% (n = 61)
by three steps. Finally, 35.5% (n = 707) of men but only 23.8%
(n = 314) of women had concordant risk grades. Concordance
was not inﬂuenced by the presence or absence of symptoms.
Concordance between calculated HF and
global risks
The 4-year HF risk and the 10-year global cardiovascular
risk were compared among 2207 eligible observations. Only
749 individuals were classiﬁed in equivalent risk groups.
The overall concordance was low (33.9%; w = 0.12) irre-
spective of the presence (30.6%, w = 0.08) or absence
(36.4%w = 0.10) of symptoms. In 45.9% (n = 1013) of
patients, the global cardiovascular risk exceeded the Fram-
ingham HF risk (Fig. 2).
a
m
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c
rigure 2. Concordance between classiﬁcation of heart failure risk
btained using the Framingham and SCORE algorithms. The percent-
ge of patients within each category (in ﬁve classes of risk) are
ndicated.
iscussion
-PREDICT is the ﬁrst survey to describe two concomitant
pproaches to HF and global cardiovascular risk assess-
ent in hypertensive adults by general practitioners in
rimary care. The physicians sampling and the patients’
hronological selection bring a noteworthy guarantee of rep-
esentativity, as well as the balanced distribution of patients
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n the three age groups. The analysis of the primary endpoint
hows that HF risk components were more frequent in men
nd in older patients. Moreover, practitioners estimated that
7% of hypertensive patients presented with a moderate or
high risk of developing HF within 4 years. This risk remains
ritical in this hypertensive population in primary care, as
ore than 13% presented with a high risk (≥ 10%), especially
ubjects older than 70 years. Given that the accurate assess-
ent of global cardiovascular risk is essential for the optimal
anagement of hypertensive adults, careful attention to
ultiple identiﬁed risk factors [19] is required in addition to
ny element of HF. In our work, most hypertensive patients
67.2%) presented with one or two cardiovascular risk fac-
ors. The number of cardiovascular risk factors increased
ith age and the presence of left ventricular hypertrophy
p < 0.001), while more than 50% of patients presented with
ssociated risk factors.
The concordance between the estimated and the cal-
ulated Framingham HF risk was fair according to the
onsidered level of risk, with physicians tending to over-
stimate low-risk patients but to underestimate high-risk
atients, whatever their age or sex. Interestingly, this sub-
ective classiﬁcation was not inﬂuenced by the presence of
ymptoms and the high-risk rate increased by almost 10%
ith age.
Similarly, the concordance between both approaches for
lobal cardiovascular risk (according to the SCORE system)
as poor: 48% of subjects had a moderate or high calcu-
ated global cardiovascular risk, while physicians attributed
moderate to high risk to 75% of their patients, hence over-
stimating the risks. A UK study [21] focused on the global
ardiovascular risk assessed in 397 hypertensive patients
ged between 60 and 79 years by GPs and practice nurses,
sing Framingham-based tables; the study revealed that the
evel of risk was estimated correctly in only 21% of patients,
nd was underestimated in 63%, without any systematic dif-
erence between estimates made by GPs and nurses.
Finally, the risk of developing HF over the next 4 years,
alculated according to the Framingham cohort, tallied
arely with the 10-year global cardiovascular risk, calcu-
ated according to the SCORE system, but this discrepancy
ould be due to the fact that the Framingham algorithm
uantiﬁes individual HF risk over the next 4 years, while
he SCORE system predicts global coronary fatal events.
hese ﬁndings highlight the need for GPs to use both tools
n order to determine accurately an individual patient’s risk
evel.
onclusion
lthough the Framingham HF risk algorithm and the SCORE
ystem have been available for many years, they are
sed rarely in routine clinical practice, particularly in
ypertensive patients, who are at high global cardiovas-
ular and HF risk. Our study shows that more than one
n 10 hypertensive patients seen in primary care is at
igh risk of HF according to the Framingham algorithm.
his algorithm appears to offer additional information to
hat provided by the SCORE system. When combined with
he fact that GPs’ estimates of global cardiovascular and
F risk correlate poorly with estimated risks, the use of
[A.A. Hagège et al.
uch validated tools in routine practice is to be encour-
ged.
onﬂict of interest
onsultant for AstraZeneca France.
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